Global Bronchopulmonary Dysplasia Treatment Market

The Global Bronchopulmonary Dysplasia Market was valued at $xx Mn in 2019 and is expected to reach $xx Mn by 2026, at a CAGR of xx%.

Market Introduction and Overview Bronchopulmonary dysplasia (BPD) is the most familiar chronic respiratory disease that results from complications related to the lung injury during the treatment of respiratory distress syndrome (RDS) in low-birth-weight premature infants, or when abnormal lung development occurs in older infants. New approaches in assisted ventilation, optimal nutrition, and pharmacologic interventions are boosting the market growth.

The key force driving the Bronchopulmonary dysplasia treatment market is the growth rate of infants who are at the high-risk of getting Bronchopulmonary dysplasia. According to research, every year, the number of infants getting affected by Bronchopulmonary dysplasia is increasing, which is propelling the demand for the treatment. Several other factors include increasing initiatives and efforts are taken by the government, favorable policies, the growing prominence of the disease, and increasing rate of premature births resulting in Bronchopulmonary dysplasia. Also, government initiatives, favorable reimbursement policies, the launch of novel drugs, strong pipeline, rising premature birth cases and an increase in health care expenditure are factors likely to fuel the global bronchopulmonary dysplasia treatment market during the forecast period.

The report contains detailed analysis of Strengths, Weaknesses, and opportunities of the key players operating in Bronchopulmonary Dysplasia Market. It also provides information on current market trends, competitive ranking analysis, regional bifurcation, turnover forecasts, industry drivers and the key challenges. The report has profiled eight key players in the market from different regions. However, report has considered all market leaders, followers, and new entrants with investors while analysing the market and estimation the size of the same. The growing healthcare infrastructure in each region is different and focus is given on availability of advanced technology and new techniques.

Segment Analysis By drug type, the bronchodilators segment is expected to reach $xx Mn in the forecast period. The combination drug consisting of LABA and inhaled corticosteroid (ICS) is a therapeutic trend observed in the market. This therapy is gaining popularity owing to its effectiveness. It increases patient compliance, as it is administered as a once-daily dose. The market is set to witness the launch of many such therapies during the forecast period. These drugs suppress the immune response in individuals with asthma and reduce bronchial hyperactivity.

There has been significant progress over the years in the management of airway disorders, bronchodilator treatment, which remains a key element in the therapy of these disorders, is still stuck in the use of β2-adrenoceptor agonists, muscarinic acetylcholine receptor (mAChR) antagonists and xanthines. In recent years, new targets for drugs to induce bronchodilation have been identified, which is fuelling the segment growth. Increase in prevalence of pulmonary disorders, growing technological advancements, and a rise in disposable income, increasing geriatric population and growing government initiatives for creating awareness among the general population are also the factors driving the segment.

By therapy, the oxygen therapy segment accounted for a share of xx% in 2020 and is expected to reach $xx Mn in the forecast period. As per the National Institutes of Health (NIH), nearly 12 million adults have been diagnosed with COPD in the U.S. and 120,000 people die each year. The increasing patient population is expected to boost the demand for oxygen therapy. One of the mainstays of the treatment of BPD patients are the maintenance of appropriate arterial oxygen levels. In addition, the advent of the technologically advanced oxygen source and delivery devices, which offers efficient patient care, is expected to boost the segment. Regional Insights North America accounted for the largest market share of xx% in 2019 and is expected to grow a CAGR of xx% in the forecast period. The high prevalence of the disease in the region and the rise in premature birth rate are factors fuelling the growth of the Bronchopulmonary dysplasia treatment market in the region. Growth in insurance coverage, presence of centers and institutes engaged in R&D and government funding are surging the North American market. Well-established healthcare infrastructure, ease of availability is also a key driver affecting the market growth.

Investments by key players in this field have boosted the market growth. The rising adoption of technologically advanced diagnostic imaging systems for gene therapy is rapidly growing the market. Europe is also expected to drive the market and the factors responsible for growth are the growing acceptance of emerging technologies, rising incidence of chronic diseases is boosting the market growth. The Asia Pacific is also expected to witness significant growth during the forecast period due to rising health care expenditures. The allocation of a large amount of healthcare expenditure for hospitals and dispensing medicines to the elderly is expected to drive the market demand.
For more information visit@ https://www.maximizemarketresearch.com/market-report/global-bronchopulmo...
Scope of the Report

By Region
• North America • Europe • South America • MEA • Asia Pacific
Key Players operating in the Global Bronchopulmonary Dysplasia Market
• Airway Therapeutics, LLC • Therabron Therapeutics • Syntrix Biosystems, Inc • CHIESI Farmaceutici S.p.A. • Meridigen Biotech • MediPost • Insmed • Martindale Pharmaceuticals

This report submitted by Maximize market Research Company

Customization of the report:

Maximize Market Research provides free personalized of reports as per your demand. This report can be personalized to meet your requirements. Get in touch with us and our sales team will guarantee provide you to get a report that suits your necessities.

About Maximize Market Research:

Maximize Market Research provides B2B and B2C research on 20,000 high growth emerging opportunities & technologies as well as threats to the companies across the Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.